Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci

Djuzenova, Cholpon S; Elsner, Ines; Katzer, Astrid; Worschech, Eike; Distel, Luitpold V; Flentje, Michael; Polat, Bülent

doi:10.1186/1748-717X-8-98

Radiation Oncology

Table 1 DNA damage measured by the histone γ-H2AX in PBMCs isolated from blood of apparently healthy donors (N) and unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro * or after 5 clinical fractions (BC patients)

From: Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci

Subject^a	Age (years)	Sex	Clinical status with respect to cancer, skin reaction to RT^b	0 Gy	0.5 Gy, 30’	0.5 Gy, 24 h	2 Gy, 24 h	72 h after 5 clinical fractions
Apparently healthy donors
N-1	27	F	n.d.	0.02	3.11		0.94
N-2	28	F	n.d.	0.04	2.60		0.86
N-3	29	F	n.d.	0.13	1.94	0.29	0.55
N-4	58	F	n.d.	0.07	2.00	0.28	0.41
N-5	58	F	n.d.	0.15	2.86	0.47	0.39
N-6	65	F	n.d.	0.12	2.73	0.42	0.74
N-7	56	F	n.d.	0.05	1.72	0.15	0.28
N-8	48	F	n.d.	0.41	2.67	0.28	0.60
N-9	41	F	n.d.	0.17	2.49	0.29	0.37
N-10	44	F	n.d.	0.07	2.09	0.19	0.34
N-11	48	F	n.d.	0.08	2.33	0.15	0.47
N-12	43	F	n.d.	0.10	2.23	0.19	0.36
Mean	45			0.12	2.40	0.27	0.53
± SD	12			0.10	0.40	0.10	0.21
Breast cancer patients
BC-01	59	F	BC, grade 3	0.70	3.29		2.59	0.32
BC-02	63	F	BC, grade 1	0.62	2.39		2.93	0.57
BC-03	45	F	BC, grade 0	0.92	2.87		3.93	0.67
BC-04	73	F	BC, grade 3	0.42	4.50		2.61	0.66
BC-05	57	F	BC, grade 1	0.07	5.48		2.50	0.49
BC-06	50	F	BC, grade 1	0.27	4.77		1.72	0.56
BC-07	63	F	BC, grade 2	0.46	5.32		3.65	0.75
BC-08	70	F	BC, grade 2	0.84	5.49		4.47	0.64
BC-12	61	F	BC, grade 3	0.25	4.71		2.26	0.57
BC-13	55	F	BC, grade 3	0.32	5.34		3.11	0.83
BC-14	54	F	BC, grade 2	0.14	3.75		1.18	0.19
BC-20	52	F	BC, grade 1	0.32	3.77		1.95	1.06
BC-23	51	F	BC, grade 1	0.12	2.67		2.25	0.77
BC-25	41	F	BC, grade 0	0.44	4.99		1.27	0.30
BC-26	63	F	BC, grade 1	0.21	3.62		1.92	0.35
BC-27	71	F	BC, grade 1	0.14	3.31		0.92	0.57
BC-28	42	F	BC, grade 0	0.10	4.29		1.29	0.35
BC-29	74	F	BC, grade 1	0.22	3.7		1.12	0.28
BC-30	46	F	BC, grade 2	0.05	3.39		0.77	0.32
BC-31	56	F	BC, grade 2	0.01	1.95		0.95	0.27
BC-32	44	F	BC, grade 2	0.08	2.98		1.08	0.28
BC-33	41	F	BC, grade 3	0.19	3.43		0.92	0.29
BC-34	38	F	BC, grade 2	0.10	3.22		0.86	0.28
BC-35	77	F	BC, grade 2	0.07	3.23		0.91	0.06
BC-36	70	F	BC, grade 1	0.06	2.72		0.81	0.18
BC-37	64	F	BC, grade 0	0.03	2.90		0.48	0.19
BC-38	73	F	BC, grade 1	0.08	2.37		0.48	0.20
BC-39	55	F	BC, grade 1	0.01	2.05	0.13	0.31	0.43
BC-40	77	F	BC, grade 2	0.05	2.24	0.11	0.15	0.34
BC-41	54	F	BC, grade 1	0.09	2.11	0.31	0.39	0.38
BC-42	49	F	BC, grade 1	0.01	2.05	0.15	0.40	0.34
BC-43	62	F	BC, grade 2	0.05	1.99	0.43	0.62	0.57
BC-44	59	F	BC, grade 1	0.04	2.54	0.41	0.75	0.18
BC-45	51	F	BC, grade 1	0.02	2.81	0.40	0.64	0.24
BC-46	62	F	BC, grade 1	0.32	3.58	0.70	0.28	0.32
BC-47	30	F	BC, grade 2	0.22	3.27	0.41	0.24	0.18
BC-48	71	F	BC, grade 2	0.26	3.48	0.46	0.59	0.51
BC-49	46	F	BC, grade 2	0.18	3.15	0.38	0.60	0.30
BC-50	48	F	BC, grade 3	0.13	3.34	0.33	0.31	0.34
BC-51	57	F	BC, grade 1	0.09	2.63	0.39	0.34	0.41
BC-52	62	F	BC, grade 2	0.09	2.54	0.25	0.36	0.31
BC053	68	F	BC, grade 2	0.09	2.23	0.20	0.34	0.16
BC-54	37	F	BC, grade 1	0.14	2.28	0.25	0.47	0.4
BC-55	67	F	BC, grade 1	0.08	2.73	0.41	0.4	0.27
BC-57	55	F	BC, grade 1	0.11	2.68	0.3	0.76	0.38
BC-58	62	F	BC, grade 1	0.06	2.62	0.31	0.6	0.32
BC-59	55	F	BC, grade 1	0.07	1.85	0.22	0.41	0.36
BC-60	65	F	BC, grade 2	0.11	3.32	0.42	0.54	0.43
BC-61	54	F	BC, grade 2	0.04	2.09	0.25	0.52	0.43
BC-62	53	F	BC, grade 2	0.06	0.06	0.19	0.14	0.38
BC-63	69	F	BC, grade 1	0.09	2.65	0.34	0.59	0.4
BC-64	81	F	BC, grade 1	0.1	2.65	0.39	0.36	0.27
BC-65	38	F	BC, grade 2	0.15	2.01	0.31	0.67	0.31
BC-66	77	F	BC, grade 1	0.14	2.29	0.3	0.64	0.27
BC-67	48	F	BC, grade 1	0.14	2.61	0.45	0.71	0.36
BC-68	49	F	BC, grade 2	0.1	2.48	0.22	0.53	0.27
BC-69	51	F	BC, grade 1	0.26	2.25	0.2	0.53	0.16
Mean	57			0.18	3.07	0.32	1.11	0.39
± SD	12			0.19	1.04	0.12	1.01	0.19

*Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Bold fonts indicate the unselected BC patients who revealed an adverse acute skin reaction to RT;
^aCase number was according to our files;
^bEarly skin reaction according RTOG score (Cox et al., 1995) [26]. RTOG grade: 1 - follicular, faint or dull erythema, dry desquamation; 2 - tender or bright erythema, moderate edema; 3 - confluent, moist desquamation, pitting edema; 4 - ulceration, haemorrhage, necrosis.
Abbreviations used: N, normal; BC, breast cancer; F, female; n.d., not determined.

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com